Summary & Overview
CPT 0254U: SMART PGT–A Embryo Aneuploidy Testing with NGS
CPT code 0254U is a Proprietary Laboratory Analyses (PLA) code for the SMART PGT–A test from Igenomix® USA, a next generation sequencing (NGS)–based assay with mitochondrial DNA scoring to detect embryo chromosomal abnormalities (aneuploidy) for use in in vitro fertilization (IVF). As a PLA code, 0254U applies to a single manufacturer-specific test and signals payer consideration of a unique laboratory service. Nationally, such PLA codes are important because they identify discrete, proprietary assays that may require individualized coverage and medical policy review.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for preimplantation genetic testing for aneuploidy, typical sites of service and service type, and an overview of what to expect in payer considerations for PLA codes. The publication summarizes benchmarking and coverage landscape themes for proprietary embryo aneuploidy testing, highlights policy implications for laboratory billing and claim adjudication, and outlines the clinical use case for embryo selection during IVF. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0254U is a Proprietary Laboratory Analyses (PLA) code for the SMART PGT–A (Preimplantation Genetic Testing – Aneuploidy) test from Igenomix® USA. The test uses next generation sequencing (NGS) and mitochondrial DNA scoring to evaluate an embryo biopsy for chromosomal abnormalities (aneuploidy) to support embryo selection during in vitro fertilization (IVF).
-
Service type: Laboratory genetic testing using NGS and mitochondrial DNA scoring for embryo aneuploidy assessment
-
Typical site of service: Fertility clinic-associated laboratory or specialized molecular diagnostics laboratory that performs embryo biopsy analysis
Clinical & Coding Specifications
Clinical Context
A 36-year-old woman undergoing in vitro fertilization (IVF) elects preimplantation genetic testing for aneuploidy (PGT‑A) using the SMART PGT‑A assay from Igenomix® USA to improve embryo selection. During IVF, mature oocytes are retrieved, fertilized (conventional IVF or ICSI), and embryos are cultured to blastocyst stage (day 5–7). A trophectoderm biopsy (typically 3–10 cells) is performed by the embryology team in the IVF laboratory and the sample is prepared for transport to the proprietary laboratory performing the SMART PGT‑A test. The assay uses next generation sequencing and mitochondrial DNA scoring to detect chromosomal aneuploidies and provide mitochondrial DNA metrics that may inform embryo viability.
The clinical workflow includes pre‑test counseling and consent, coordinated scheduling of biopsy on the embryo culture day, sample labeling and chain‑of‑custody documentation, specimen transport to the performing lab, laboratory processing with NGS and mtDNA analysis, and reporting of results back to the reproductive endocrinologist and patient to guide embryo transfer decisions. Typical site of service is an outpatient IVF clinic with embryo biopsy performed in the embryology laboratory; analytic testing occurs at the proprietary reference laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default, no modifier | Standard reporting when no special circumstances apply |